Placebo News and Research

RSS

SYMBICORT now available in the U.S. for asthma

AstraZeneca has announced today that SYMBICORT (budesonide/formoterol fumarate dihydrate) pressurized metered dose inhaler (pMDI) is now available in the United States for the long-term maintenance treatment of asthma in patients 12 years of age and older.

26 Jun 2007

Stem cells to repair damaged heart muscle

In the first trial of its kind in the world, 60 patients who have recently suffered a major heart attack will be injected with selected stem cells from their own bone marrow during routine coronary bypass surgery.

23 Jun 2007

Gene therapy for Parkinson's disease is safe and some patients benefit

A novel gene therapy technique is safe and may be effective at staving off worsening symptoms of Parkinson's disease, according to the first scientific review of a dozen patients who have received the treatment over the last three years.

23 Jun 2007

Polyethylene laxative safe for patients suffering from chronic constipation

A clinical trial including 50 medical centers and 304 patients has confirmed that polyethylene (PEG) laxative is safe for patients suffering from chronic constipation.

23 Jun 2007

Omega-3 supplements can help reduce Alzheimer's symptoms in some cases

Omega-3 supplements can, in certain cases, help combat the depression and agitation symptoms associated with Alzheimer's disease, according to a clinical study conducted at the Swedish medical university Karolinska Institutet.

23 Jun 2007

Truth on postmenopausal hormone therapy and coronary disease

With each new publication of coronary artery disease (CAD) data from the Women's Health Initiative (WHI) study, the inevitable reaction is ,Why on earth did the WHI investigators claim in 2002-2004 that postmenopausal hormone therapy has deleterious effects on the risk for CAD, when, from the beginning, they were aware of the importance of the age factor in this clinical scenario".

23 Jun 2007

Genzyme files for FDA approval of single-treatment Synvisc-One

Genzyme Corp. has announced that it has filed with the U.S. Food and Drug Administration (FDA) for approval of Synvisc-One, the single treatment of Synvisc (hylan G-F 20) that provides up to six months of pain relief from osteoarthritis (OA) of the knee.

23 Jun 2007

Estrogen use lowered one risk factor for heart disease among some younger postmenopausal women

A follow-up study to the federally funded Women's Health Initiative should help allay one concern in a subset of women in their 50s who are considering taking estrogen to relieve hot flashes.

23 Jun 2007

Estrogen HRT can limit plaque accumulation in arteries

Estrogen can limit significantly the accumulation of plaque in the arteries of women in their 50s, according to a study published on Thursday in the New England Journal of Medicine, the Milwaukee Journal Sentinel reports (Newson, Milwaukee Journal Sentinel, 6/20).

22 Jun 2007

Stem cells to repair damaged heart muscle

22 Jun 2007

HRT not such a bad idea after all!

Older women struggling to cope with the symptoms of the menopause will be reassured by the latest research into hormone replacement therapy (HRT).

21 Jun 2007

More effective treatment for malaria control during pregnancy in Africa

A review of previous studies indicates that two doses of a malaria preventive therapy during pregnancy provides substantial benefit to HIV-negative women in Africa, with more frequent dosing apparently necessary for HIV-positive women, according to an article in the June 20 issue of JAMA.

20 Jun 2007

Remicade helps those with ankylosing spondylitis

Data presented at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology showed that patients with ankylosing spondylitis (AS) who received REMICADE, (infliximab) over two years experienced significant improvement in spinal mobility.

19 Jun 2007

Extended exposure to the psoriasis medication etanercept reduces psoriasis severity without increased adverse events

Extended exposure to the psoriasis medication etanercept does not appear to cause more infections or adverse events than placebo, and improvements in several measures of disease severity were observed for up to 96 weeks of therapy, according to a study in the June issue of Archives of Dermatology.

19 Jun 2007

Results of Tocilizumab study

Nearly half (43.9%) of rheumatoid arthritis (RA) patients receiving tocilizumab 8mg/kg, in addition to ongoing methotrexate therapy experienced a 50% (ACR50) improvement in symptoms at 24 weeks and more than one fifth achieved a 70% symptom improvement, according to results of a study presented at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain.

19 Jun 2007

Analysis of steroids as a treatment for sudden hearing loss

Although steroids are the most widely used treatment for sudden hearing loss, little scientific evidence supports their use or that of any other therapies for this condition, according to a systematic review and meta-analysis both published in the June issue of Archives of Otolaryngology, Head & Neck Surgery.

19 Jun 2007

Bone erosion reduced by denosumab

Treatment with denosumab 60 mg and 180 mg (with background methotrexate) reduces the progression of bone erosion according to results of a 227 patient Phase II trial presented at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain.

19 Jun 2007